Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
Healthy Volunteers
NCT06584045

Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)

Led by Tongji Hospital · Updated on 2025-04-08

250

Participants Needed

1

Research Sites

269 weeks

Total Duration

On this page

Sponsors

T

Tongji Hospital

Lead Sponsor

J

Jianmin Pharmaceutical Group Co., LTD.

Collaborating Sponsor

AI-Summary

What this Trial Is About

Based on the records of traditional Chinese medicine, CBS has the functions of purifying the heart, eliminating phlegm, stimulating bile secretion, and soothing the nerves. It has the ability to alleviate fever, coma, delirium, epilepsy, convulsions in youngsters, dental caries, throat swelling, mouth ulcers, carbuncle, and furuncle. Encephalitis is a neurological condition characterized by widespread or multiple inflammation of brain tissue. The causes of encephalitis are many and can stem from infectious organisms or be induced by autoimmune reactions, the latter being referred to as autoimmune encephalitis (AE). The yearly occurrence rate of encephalitis is 12.6 per 100,000 individuals. Among these cases, approximately 40-50% are caused by infectious factors, whereas 20-30% are attributed to autoimmune encephalitis (AE). The development of viral encephalitis involves the direct invasion of brain tissue by the virus and the immune response of the body to viral antigens. The virus multiplies extensively, leading to the degeneration of neurons, necrosis, the proliferation of glial cells, and the infiltration of inflammatory cells. These severe tissue reactions can result in the formation of demyelinating lesions and damage to blood vessels and the areas surrounding them. Additionally, vascular lesions affect the circulation in the brain and worsen the damage to brain tissue. The development of AE involves several factors, including molecular mimicry, the activation of latent antigen epitopes, the spread of antigen epitopes, and the disruption of the innate immune system caused by persistent pathogen infection. The mechanisms that are clearer can be summarized as follows: (1) Decrease in the number of receptors on the surface due to cross-linking and internalization: Anti-NMDAR antibodies have the ability to attach to NMDAR on the postsynaptic membrane, resulting in a reduction of NMDAR surface density through cross-linking and internalization. This reduction leads to a decrease in NMDAR-mediated current, which in turn causes learning and memory defects. (2) Protein-protein interaction disruption: Anti-LGI1 antibodies can disrupt the binding between LGI1 and ADAM23 on the presynaptic membrane and ADAM22 on the postsynaptic membrane. This disruption leads to a decrease in the density of anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR). According to the aforementioned background processes, along with the most recent research, there was a decrease in the abundance of gut flora in patients with AE. Transplanting the fecal bacteria of individuals with anti-NMDAR encephalitis into mice's intestines resulted in cognitive impairment in the animals. This indicates that the brain-gut axis may have a significant role in the development of anti-NMDAR encephalitis. From a clinical perspective, patients consume CBS orally in order to achieve its therapeutic benefits. The primary constituents, bilirubin and bile acid, have been documented to possess regulatory effects on the gut microbiota. Thus, we hypothesize that CBS is probable to have neuroprotective and anti-inflammatory impacts on the brain through alterations in the intestinal microbiota and regulation of the brain-gut connection. CBS is expected to decrease the occurrence of symptomatic seizures and enhance the patient's level of consciousness and cognitive abilities.

CONDITIONS

Official Title

Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 80 years able to understand the study and provide informed consent
  • Diagnosed with autoimmune encephalitis or viral encephalitis according to established clinical and laboratory criteria
  • Able to exclude tumors or malignancies before baseline visit
  • Stable neurological examination within 30 days before baseline
  • For women and men of childbearing potential, agreement to use contraception during and 30 days after treatment
  • For specific autoimmune encephalitis subtypes, meet detailed diagnostic criteria including antibody tests and symptom onset within defined timeframes
  • Healthy adults aged 18 or older without underlying diseases for the healthy cohort
Not Eligible

You will not qualify if you...

  • Any serious cardiac, endocrine, hematologic, hepatic, immune, infectious, metabolic, pulmonary, neurological, psychiatric, renal, or other major diseases preventing safe participation
  • Untreated teratoma or thymoma at baseline
  • Other causes of symptoms such as central nervous system infections or metabolic encephalopathies
  • History of herpes simplex encephalitis within 24 weeks
  • Surgery within 4 weeks before baseline except minor procedures
  • Planned surgeries during the study except minor ones
  • History of severe allergic reactions to study components
  • Current or recent malignant diseases except certain cured skin cancers
  • History or active gastrointestinal diseases or symptoms interfering with participation
  • Recent blood, plasma, or platelet donation
  • Active suicidal thoughts or recent suicide attempts
  • Abnormal blood pressure or significant heart conduction problems
  • Planned elective procedures after consent
  • Conditions affecting drug absorption
  • History of heparin-induced thrombocytopenia
  • Positive HIV or active hepatitis B or C infections
  • Severe or recent infections
  • Recent live vaccinations
  • Contraindications to standard salvage therapies
  • History of certain radiation or stem cell therapies
  • Abnormal laboratory tests considered clinically significant
  • Pregnant, lactating, or planning pregnancy during study
  • History of substance abuse within the past year
  • Participation in another clinical trial within 90 days
  • Hearing, vision, or cognitive impairments preventing assessments
  • Other reasons judged by investigators as unsuitable for participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, China, 430000

Actively Recruiting

Loading map...

Research Team

K

Ke Shang, MD

CONTACT

K

Ke Shang, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here